Therapeutic Title Current and Future Therapies for Lung Cancer Sub title A Therapeutic & Competitive Insight Author BioSeeker Publication date March 2006 ISBN - n/a - Pages 115 Price pdf £1330   |   print n/a Summary Lung cancer is the third most common malignant disease and the first leading cause of cancer death in the western world. Yet platinum agent constitutes the current mainstay of front-line metastatic lung cancer treatment. There are currently two platinum-based compounds that are marketed and clinically used worldwide as treatment for NSCLC: cisplatin and carboplatin. These two drugs are combined with paclitaxel, docetaxel, gemcitabine or vinorelbine to build the first-line treatment options. Several different studies have been comparing or are comparing differ combinations of these drugs. Lately gefitinib, pemetrexed and erlotinib have entered the market and are initially used in second or third-line treatments. The third-generation chemotherapeutic agents have expanded the therapeutic options in the treatment of advanced NSCLC. However, despite their contributions, science has reached a therapeutic plateau. Both Avastin and Efaproxyn have generated exciting data. In this report we are not only describing the progress of different combinations of approved drugs but as well the progress of 21 late stage drug candidates are described and analysed. Progress profiles and structured information will alow you to pin-point your knowledge-base in a most costeffective way. By gathering information around most drugs under development for lung cancer and specially the late stage pipeline it is has been clear that four major therapeutic strategies generated most interesting data. With this report you will be able to track down and foresee activities associated with the development of new treatments for lung cancer. According to market analytical studies, the NSCLC drug market is predicted to exceed $4 billion between 2010 and 2015. Chemotherapy drugs will experience generic erosion and three major chemotherapy drugs go off patent before 2012; Aventisï Taxotere (docetaxel), Bristol-Myers Squibbïs Paraplatin (carboplatin) and Eli Lillyïs Gemzar (gemcitabine). Scope of this report • Thorough examination of status and impact of many novel drugs in development • Discussion of the challenges in current drug development, including future clinical trials to be made, collaborations and inclusion of novel endpoints. • Case studies on major lung cancer drugs on market Key reasons to read this report • Explore the strengths and weaknesses associated with compounds in clinical development. • Scientific rationale for novel therapeutics in lung cancer, and the results of clinical trials to date. • Gain insight into the current challenges and commercial opportunities associated with lung cancer Drugs included in this study Affinitak, Aptosyn, Bevacizumab, Carboxyamidotriazole, Cetuximab, CI-994, Docetaxel, Efaproxyn, Erlotinib, Gefitinib, Gemcitabine, Genasense, Lapatinib IGN-101, Mitumomab, Neovastat, Paclitaxel, Panitumumab, Pemetrexed, Targretin, Telcyta, Tirapazamine, Trastuzumab, Vinflunine, Vinorelbine, Xcytrin, ZD-6474 Companies included in this study Abgenix, Aphton, AstraZeneca, Bristol-Myers Squibb, Cell Pathways, Eli Lilly, Genentech, Genta, GlaxoSmithKline, ImClone, ISIS Pharmaceuticals, Ligand Pharmaceuticals, OSI Pharmaceuticals, Pfizer, Pharmacyclics, Sanofi-Aventis, Telik TABLE OF CONTENTS Executive Summary 2 Cancer Highlights 3 Methodology 4 Table of Contents 4.1 List of boxes 4.2 List of tables 4.3 Appendices 5 Introduction 5.1 Current Treatment Strategies 5.2 Disease Definition 5.3 Etiology & Pathophysiology 5.4 Prognosis 5.5 Epidemiology 6 Progress in current treatment strategies 6.1 Improvements adding microtubule inhibitor 6.2 Improvement of disease related symptoms in elderly patients 6.3 Toxicity profile favored 6.4 A new formula 6.5 Monotherapy? 6.6 Failed to demonstrate a survival advantage 6.7 Reduction in mortality risk 7 Key Drug Strategies in Lung Cancer 7.1 Apoptosis 7.2 Antiangiogenesis and Antivascular Agents 7.2.1 EGFR and VEGFR as target 7.3 Immunotherapy 8 Competitive Landscape in Lung Cancer Drug Development: The Late Stage Pipeline 8.1 Grade 4 adverse events 8.2 No new remarks 8.3 No significant effect on overall survival 8.4 Bristol Myers Squibb entered into an agreement 8.5 Many uncertainties remain 8.6 Development terminated 8.7 Continuing Enrollment 8.8 Apoptotic inducer 8.9 Fully-human monoclonal antibody 8.10 Eagerly awaiting data 8.11 Mutations and response 8.12 Statistically and clinically significant survival advantage 8.13 Anti-idiotypic monoclonal antibody 8.14 Shift in the development focus 8.15 Sensitizer 8.16 Treatment in earlier-stage cancer could be more effective 8.17 Discontinued radiosensitizer 8.18 Improvement in chemoradiotherapy 8.19 Progress on HDAC inhibitor 8.20 Progress Analysis Carboxyamidotriazole 8.21 Chemotherapy naïve subjects 9 Disclaimer 9.1 Liability 9.2 Completeness 10 Appendix 1. Treatment Guide Lines* 10.1 References 11 Appendix 2: Selected Company Profiles 11.1 Abgenix 11.2 Aphton 11.3 AstraZeneca 11.4 Bristol-Myers Squibb 11.5 Eli Lilly 11.6 Genentech 11.7 Genta 11.8 GlaxoSmithKline 11.9 ImClone 11.10 ISIS Pharmaceuticals 11.11 Ligand Pharmaceuticals 11.12 OSI Pharmaceuticals 11.13 Pfizer 11.14 Pharmacyclics 11.15 Sanofi- Aventis 11.16 Telik 12 Appendix 3 Progress profiles on approved drugs 12.1 Docetaxel 12.2 Vinorelbine 12.3 Gemcitabine 12.4 Paclitaxel 12.5 Pemetrexed 12.6 Gefitinib 12.7 Erlotinib 13 Drug Index 14 Company Index List of Boxes Box 1: Scientific Data on Docetaxel Box 2: Quick Facts – Vinorelbine Box 3: Scientific Data on Vinorelbine Box 4: Quick Facts – Gemcitabine Box 5: Scientific Data on gemcitabine Box 6: Scientific Data on Pemetrexed Box 7: Quick Facts – pemetrexed Box 8: Quick Facts – Gefitinib Box 9: Scientific Data on Gefitinib Box 10: Quick Facts – Erlotinib List of Tables Table 1: Chemotherapeutic drugs for treatment of NSCLC Table 2. Near Term Approved Drugs for the Treatment of NSCLC Table 3: Chemotherapy Drugs off Patent Table 4 Generalized Illustration, Depicting the Key Elements Involved in the Apoptotic Pathways Table 5 VTA agents under development Table 6 EGFR or VEGFR inhibitors Table 7: FMS-like tyrosine kinases and their Synonyms Table 8: Fms-related Tyrosine Kinase Targets in Development Table 9: Protein Kinase Targets in Clinical Trials for Lung Cancer Table 10 Cancer immunotherapy strategies Table 11 Recently presented studies Lapatinib Table 12 Recently presented studies ZD-6474 Table 13 Recently presented studies vinflunine Table 14 Recently presented studies Panitumumab Table 15 Recently presented studies Genasense Table 16 Recently presented studies cetuximab Table 17 Recently presented studies bevacizumab Table 18 Recently presented studies bexarotene Table 19 Recently presented studies Xcytrin Appendices 10 Appendix 1. Treatment Guide Lines* 11 Appendix 2: Selected Company Profiles 12 Appendix 3 Progress profiles on approved drugs Therapeutic

No additional author information available for this product